References
Catalona WJ: Prostate Cancer. Grune and Stratton, Inc., Orlando, FL, 1984
Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of prostate? J Clin Oncol 3:1013–1021, 1985
Evans WK, Shepherd FA, Mullis B: Phase II evaluation of lonidamine in patients with advanced malignancy. Oncology 41 (Suppl 1):69–77, 1984
Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman, MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–841, 1985
Kim JH, Alfieri A, Kim SH, Young CW, Silvestrini B: Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine. Oncol 41 (Suppl 1):36–38, 1984
Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A: In vitro and in vivo potentiation by lonidamine of the antitumor effect of Adriamycin. Anticancer Res 6:1245–1250, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, D.J., Aitken, S.E., Irvine, A.H. et al. Phase II study of lonidamine in metastatic prostatic carcinoma. Invest New Drugs 9, 343–344 (1991). https://doi.org/10.1007/BF00183577
Issue Date:
DOI: https://doi.org/10.1007/BF00183577